U.S. Specialty Stores Stock News

If you are wondering whether Lam Research shares still offer value after a strong run, or if you are turning up late to the party, this breakdown can help you frame the risk and reward trade off more clearly. The stock closed at US$265.55 and has posted returns of 0.1% over 7 days, 13.8% over 30 days, 43.5% year to date, 300.9% over 1 year, 449.5% over 3 years and 339.0% over 5 years. Recent headlines around Lam Research have focused on its role in semiconductor equipment, its exposure to...

Wondering whether Valley National Bancorp at around US$13.25 is offering fair value or an appealing entry point? This article walks through what the current price could imply for you as a shareholder. The stock has moved 0.8% over the last 7 days, 10.4% over the past month, 13.3% year to date, 60.0% over 1 year and 78.5% over 3 years, compared with a 17.8% return over 5 years. Recent coverage has focused on how regional banks are being reassessed by investors, and how balance sheet strength,...

Medline stock snapshot after recent moves Medline (MDLN) has attracted fresh attention after recent trading, with the share price at $47.16 and single-day, week, and month returns of around 1%, 2%, and 11% respectively. See our latest analysis for Medline. Over the past month Medline has logged an 11.0% share price return and a 16.1% year to date share price return, suggesting near term momentum is firming even though very short term moves have been softer. If you are comparing Medline with...

Moody's (MCO) opened 2026 with Q1 revenue of US$2.1b and basic EPS of US$3.74, setting the tone for how its profitability story is developing against a US$466.72 share price. Over recent quarters, revenue has moved from US$1.67b in Q4 2024 to between US$1.89b and US$2.08b across the last five reported periods, while quarterly basic EPS ranged from US$2.18 to US$3.74, underscoring how earnings power has tracked alongside higher net income figures. With a trailing net margin cited at 31.7%, the...

Highwoods Properties (NYSE:HIW) has authorized a $250 million share repurchase program. The company plans to fund the buybacks through sales of non core assets in its portfolio. The move reflects a shift in how Highwoods is choosing to allocate capital between assets and its own shares. Highwoods Properties enters this announcement with its shares recently closing at $23.74. The stock is up 2.4% over the past week and 11.7% over the past month, while the year to date return stands at a...

If you are wondering whether Public Service Enterprise Group at around US$78.51 is offering fair value or a margin of safety right now, this article breaks down what the current price might be indicating. The stock is currently around US$78.51, with returns of a 3% decline over the past week, a 1.6% decline over the past month, a 3.1% decline year to date, and a 1% decline over 1 year, but gains of 38.8% over 3 years and 48.6% over 5 years that some investors may see as relevant context when...

In April 2026, Andretti Performance announced a partnership making Velo3D the official sponsor and additive manufacturing technology provider for two 2026 IMSA Michelin Pilot Challenge events, featuring Velo3D branding on the No. 43 Porsche at Laguna Seca and Indianapolis and race-ready components produced with its metal 3D printing systems. A custom aluminum CP1 radio controls mounting bracket, produced using Constellium’s Aheadd CP1 alloy and generative design tools, puts Velo3D’s...

Recent share performance and business overview Dream Finders Homes (DFH) has drawn attention after recent share price moves, with a return of about 10% over the past month and a decline of roughly 19% over the past 3 months. The US homebuilder, headquartered in Jacksonville, Florida, reports revenue of about US$4.3b and net income of roughly US$203.7m. This reflects its mix of single family homebuilding and related financial services across several regional segments. See our latest analysis...

EQT (EQT) kicked off Q1 2026 with revenue of US$3.6 billion and basic EPS of US$2.38, alongside trailing twelve month revenue of US$9.4 billion and EPS of US$5.31. This sets a clear earnings bar for investors tracking the story. Over recent quarters the company has seen revenue move from US$2.4 billion in Q1 2025 and US$1.8 billion in Q4 2024 to US$3.6 billion in the latest quarter. Basic EPS has increased from US$0.40 and US$0.70 in those same periods to US$2.38, putting the focus firmly on...

If you are wondering whether California Resources at around US$64.65 is still offering value or starting to look fully priced, this breakdown will help you make sense of what the current market price might be implying. The stock has been relatively flat over the last 7 days with a 0.4% decline, but over longer periods it has delivered returns of 1.3% over 30 days, 39.4% year to date, 91.4% over 1 year, 81.2% over 3 years and 207.3% over 5 years. Recent coverage of California Resources has...

Why Star Bulk Carriers Is On Investors’ Radar Star Bulk Carriers (NasdaqGS:SBLK) has drawn attention after a strong year of share-price and total-return performance, putting its dry bulk shipping business, financial profile, and valuation in sharper focus for income and value oriented investors. See our latest analysis for Star Bulk Carriers. Momentum has been building, with a 1 month share price return of 8.81% and a 90 day share price return of 15.76%. The 1 year total shareholder return of...

Ardelyx (NasdaqGM:ARDX) appointed Felecia W. Ettenberg as Chief Legal Officer, succeeding Elizabeth Grammer. The transition follows Grammer’s 16 year tenure in the role. Ettenberg brings extensive legal and regulatory experience from a leading pharmaceutical company. Ardelyx focuses on therapies in the biopharmaceutical space, where regulatory scrutiny, patent protection, and compliance requirements shape how companies operate. A new Chief Legal Officer sits at the center of these issues,...

Veeco Instruments stock in focus Veeco Instruments (VECO) is back on many investors’ screens after recent share price moves, with the stock closing at $50.37 and posting double digit returns over the past month and past 3 months. See our latest analysis for Veeco Instruments. The recent 7 day share price return of 18.1% and 30 day share price return of 59.4% sit alongside a 1 year total shareholder return of 176.8%. This points to strong momentum that has been building over time. If you are...

In recent days, Stanley Black & Decker announced that CEO Donald Allan will move to Executive Chair while Chris Nelson becomes CEO on October 1, alongside updates on tariff headwinds, supply chain transformation, and margin goals. The company also emphasized progress toward its multi‑year cost-reduction program and a 35%-plus gross margin target, underscoring management’s focus on operational discipline and innovation amid a challenging backdrop. Next, we’ll examine how this leadership...

Montaka Global Investments recently highlighted KKR & Co. Inc. in its first-quarter 2026 investor letter, citing strong fundamentals and an expectation that fee-related earnings could grow by more than 20% per annum in 2026. At the same time, Apollo Global Management’s agreement to purchase a 40% stake in Pembina Gas Infrastructure from KKR underscores how asset sales and partnerships may influence KKR’s fee profile and capital deployment. Next, we’ll examine how Montaka’s focus on KKR’s...

Aura Minerals (AUGO) recently secured Board approval for the Era Dorada Project, a planned US$382.0 million gold development with an expected 17 year life, along with an advanced community water treatment initiative. See our latest analysis for Aura Minerals. That project approval comes after a sharp re rating in Aura Minerals, with a 30 day share price return of 49.63% and a year to date share price return of 95.84%, on top of a very large 1 year total shareholder return. This suggests...

If you are wondering whether Merchants Bancorp at around US$49.43 is still attractively priced after its recent run, this article walks through what the current valuation might be telling you. Over the short term, the stock has posted returns of 5.5% over 7 days and 18.6% over 30 days, with longer term returns of 49.0% year to date and 53.5% over 1 year providing useful context for where sentiment currently sits. Recent company news, regulatory filings or sector updates help explain why...

If you are considering whether Century Communities at around US$63.82 represents value or risk, this breakdown can help you understand what you are actually paying for. The share price has recently been active, with returns of 8.5% over 7 days, 11.0% over 30 days, and 8.3% year to date. This may be of interest if you are tracking momentum and changes in sentiment. Recent coverage has focused on Century Communities as part of a broader look at US homebuilders, with attention on how individual...

Why ZenaTech’s latest expansion is on investors’ radar ZenaTech (ZENA) is drawing attention after opening new offices in Seoul and London. These moves are aimed at supporting its ZenaDrone, Drone as a Service, and enterprise SaaS operations across APAC and EMEA. See our latest analysis for ZenaTech. At a share price of $2.24, ZenaTech has seen a 9.27% 1 day share price return and 5.66% 7 day share price return, but a 55.47% 90 day share price decline. Its 1 year total shareholder return of...

Leidos Holdings (NYSE:LDOS) and Havoc have agreed to integrate collaborative autonomy technology across fleets of unmanned air and sea vehicles. The partnership aims to allow a single operator to coordinate multiple unmanned platforms at once. A large scale, real world demonstration of the joint system is planned for late 2026. For investors tracking NYSE:LDOS, this partnership arrives as the shares trade around $150.71, with a return of 7.2% over the past year and 74.4% over three years...

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its Phase 2/3 LUMINA trial for mangaciclanol, a manganese based MRI contrast agent. The agent holds FDA Fast Track designation and is being studied as a potential alternative to gadolinium based contrast agents. The company highlights potential benefits related to patient safety, supply reliability, and reduced reliance on rare earth elements. GE HealthCare enters this trial with its shares at $71.38 and a mixed...

Triple I partnership brings Faraday Future’s AI robotics into classrooms Faraday Future Intelligent Electric (FFAI) has drawn fresh attention after partnering with education institution Triple I to launch an Embodied AI robotics summer camp and broader EAI education programs in Irvine, California. This education focused move links the company’s EAI robots directly with K 12 students, parents, and teachers, giving investors a clearer view of how Faraday Future aims to apply its robotics...

Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for multiple immune mediated diseases. Biogen will lead development and commercialization of felzartamab in Greater China, a key market for conditions such as IgAN and PMN. For investors tracking Biogen, this move adds a late stage immunology asset to a pipeline already focused on serious...

If you are wondering whether Xcel Energy’s share price still reflects fair value or if the market is overlooking something, this article breaks down what the current price might be telling you. The stock last closed at US$78.11, with returns of 1.5% over 30 days and 12.6% over the past year. This may signal that market expectations and perceived risk have shifted over time. Recent attention on utilities, energy infrastructure and the broader power grid has kept Xcel Energy on many investors’...